0
0
Ibuprofen and paracetamol—two of the most commonly used over-the-counter painkillers worldwide—may be silently accelerating one of the globe’s most urgent health crises: antibiotic resistance. Groundbreaking research from the University of South Australia published in August 2025 reveals that these trusted medications not only drive antibiotic resistance when taken individually but amplify it synergistically when used together alongside antibiotics such as ciprofloxacin. The findings raise serious public health concerns, especially for older adults in residential aged care facilities where polypharmacy is common.
Key Findings of the Study
This pioneering study tested the interaction of nine commonly used non-antibiotic medications, including ibuprofen, paracetamol (called acetaminophen in some countries), and ciprofloxacin—a broad-spectrum antibiotic frequently prescribed for gastrointestinal, urinary tract, and skin infections—against the bacterium Escherichia coli (E. coli). E. coli is a common pathogen responsible for a wide range of infections.
Researchers found that exposure to ibuprofen and paracetamol significantly increased the rate of genetic mutations in E. coli, making the bacterium more resistant to ciprofloxacin. Moreover, when ibuprofen and paracetamol were combined with ciprofloxacin, the mutation rate and bacterial resistance escalated markedly. Alarmingly, the increased resistance affected multiple classes of antibiotics, not just ciprofloxacin, suggesting a broader potential impact on antimicrobial treatment failure.
The study identified that these painkillers activate bacterial defense mechanisms that expel antibiotics, rendering treatment less effective. The mutation rate increased up to 12 times, supporting a faster growth and survival of resistant E. coli strains.
Expert Perspectives
Associate Professor Rietie Venter, the lead researcher and microbiologist at the University of South Australia, emphasized the urgent implications of these findings. She noted that while antibiotics have traditionally carried focus for driving resistance due to misuse and overuse, this research highlights that non-antibiotic drugs like ibuprofen and paracetamol can also contribute significantly to this threat.
“Antibiotics have long been vital in treating infectious diseases, but their widespread overuse and misuse have driven a global rise in antibiotic-resistant bacteria,” Assoc Prof Venter explained. “This study reveals that medications commonly given for pain and fever are not innocent bystanders but active contributors to the problem, especially in aged care settings where patients often receive multiple medications. The synergy between these painkillers and antibiotics accelerates bacterial mutation and resistance development”.
Professor Mark Morgan, Chair of the RACGP Expert Committee on Quality Care, echoed these concerns, urging clinicians to “constantly consider deprescribing” to prevent inadvertent harm. He described this development as a “novel way common medicines might be contributing to harm,” urging a reconsideration of how painkillers and antibiotic prescriptions are co-managed.
Context and Background
Antimicrobial resistance (AMR) is widely recognized by the World Health Organization (WHO) as one of the top global public health threats. Data revealed antibiotic-resistant bacteria were directly responsible for 1.27 million deaths worldwide in 2019, part of an estimated 4.95 million deaths associated with AMR overall. Resistance develops as bacteria evolve defenses against antibiotic drugs, making infections harder or impossible to treat, increasing suffering, transmission, and mortality.
While the primary driver of AMR is antibiotic overuse and misuse—such as incomplete courses or unnecessary prescribing—this new research underscores additional contributors, including non-antibiotic medications widely perceived as harmless. Polypharmacy in aged care facilities, where multiple medications including painkillers, sleep aids, blood pressure, and diabetes drugs are commonly prescribed, may create ideal environments for resistant bacteria to thrive and evolve.
Implications for Public Health and Daily Decisions
This discovery highlights the need for heightened awareness among healthcare providers and patients regarding the broader impacts of common medications on antibiotic efficacy. For patients, particularly older adults and those in long-term care, judicious use of painkillers like ibuprofen and paracetamol alongside antibiotics may be warranted to reduce risk of accelerating resistance.
Clinicians should carefully evaluate medication regimens in vulnerable populations, considering deprescribing where safe to do so and seeking alternatives when possible. Public health strategies must incorporate education on medication interactions and advocate for prudent prescribing of both antibiotics and common over-the-counter drugs to help curb the rise in resistant infections.
Limitations and Counterpoints
The study’s findings stem from controlled laboratory experiments focused on E. coli and ciprofloxacin interactions, which may not capture the full complexity of human microbiomes and diverse bacterial species in clinical settings. Further research in clinical populations is necessary to confirm the extent to which ibuprofen and paracetamol impact antibiotic resistance in vivo.
Moreover, while the study highlights genetic mechanisms of resistance, it does not imply that patients should discontinue these painkillers without medical advice. These medications remain essential tools for managing pain and fever, and their benefits often outweigh risks in many situations.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
